Editas Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
EDIT$2.75+7.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(amounts in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $146,645 | $131,541 |
| Marketable securities | — | 138,372 |
| Accounts receivable | 15,176 | 16,266 |
| Prepaid expenses and other current assets | 2,074 | 3,136 |
| Total current assets | 163,895 | 289,315 |
| Property and equipment, net | 3,542 | 14,497 |
| Right-of-use assets | 16,121 | 32,554 |
| Restricted cash and other non-current assets | 2,976 | 5,223 |
| Total assets | $186,534 | $341,589 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,605 | $5,493 |
| Accrued expenses | 32,610 | 45,859 |
| Liability for sale of future revenues, current | 5,000 | 5,000 |
| Deferred revenue, current | — | 6,221 |
| Operating lease liabilities, current | 6,031 | 14,652 |
| Total current liabilities | 46,246 | 77,225 |
| Operating lease liabilities, net of current portion | 12,071 | 20,380 |
| Liability for sale of future revenues, net of current portion | 53,605 | 52,434 |
| Deferred revenue, net of current portion | 44,509 | 54,204 |
| Other non-current liabilities | 2,815 | 3,072 |
| Total liabilities | 159,246 | 207,315 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding | — | — |
| Common stock, $0.0001 par value per share: 390,000,000 and 195,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 97,866,996 and 82,734,696 shares issued and outstanding, at December 31, 2025 and December 31, 2024, respectively | 10 | 8 |
| Additional paid-in capital | 1,655,781 | 1,602,441 |
| Accumulated other comprehensive income | — | 268 |
| Accumulated deficit | (1,628,503) | (1,468,443) |
| Total stockholders’ equity | 27,288 | 134,274 |
| Total liabilities and stockholders’ equity | $186,534 | $341,589 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.